No Data
6-K: Report of foreign private issuer (related to financial reporting)
Hutchmed (China) (00013.HK) plans to hold a board of directors meeting on July 31 to approve its mid-term performance.
Hutchmed (China) (00013.HK) announced on June 26th that the company will hold a board meeting on Wednesday, July 31st, 2024 to approve the mid-term performance of the company and its subsidiaries for the six months ending on June 30th, 2024 (including) and release it at 7:00 pm that day (Hong Kong time).
Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating
GF Sec: Rated Hutchmed (China) as a "buy", with a target price of HKD 41.16.
GF Securities expects Hutchmed (China) to have a net income attributable to shareholders of -$116 million, $100 million, and $116 million for the years 2024-2026, respectively.
Hutchmed (China) (00013) will introduce the latest research and development progress on July 9th.
Hutchmed (China) Limited announced today in a statement that it will launch in 2024...
Fruquintinib's European stock price fell more than 20%, Hutchmed (China)'s stock price rise failed as a wind vane?
The key trends of Fruquintinib are gradually becoming a market investment and a direction indicator for hutchmed (china). However, sometimes the direction indicator may not react in time.
DailyHunt : Do you think is ready?
Momentum TraderOP DailyHunt: Already Bo from pivot. Don’t chase high!